Financial Data and Key Metrics Changes - The company ended the quarter with $108 million in cash and cash equivalents, with combined operating revenue, interest, and investment income of $43.6 million, marking a significant increase from approximately $2 million in the same quarter last year [11][12] - The loss from operations was $3.7 million, while non-GAAP adjusted EBITDA was a positive $6.6 million, an improvement of approximately $23 million from last year's negative $16.7 million [11][12] - Gevo North Dakota generated income from operations of $12.3 million and a positive non-GAAP adjusted EBITDA of $17.8 million [11] Business Line Data and Key Metrics Changes - Gevo North Dakota has become a core earnings engine, demonstrating reliable energy production and efficient carbon capture, contributing significantly to the company's financial performance [12] - Gevo R&G generated income from operations of $0.5 million and positive non-GAAP adjusted EBITDA of $2.7 million [11] Market Data and Key Metrics Changes - The company successfully sold all of its 2025 Section 45(z) clean fuel production credits for a total of $52 million, with net proceeds of approximately $29 million received so far [12][13] - The company is expanding its carbon dioxide removal (CDR) credit sales, with expectations to grow from $1 million in Q2 to $3-$5 million by the end of 2025 [17] Company Strategy and Development Direction - The company aims to monetize carbon as a key initiative, viewing it as an important co-product that can unlock economics for growth products like jet fuel [5][8] - Plans to build a 30 million-gallon jet fuel plant (ATJ30) at Gevo North Dakota are underway, with expected adjusted EBITDA uplift of about $150 million from this addition [9][27] - The company is focusing on incremental expansions and optimizing existing operations before pursuing larger capital projects [8][50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the business environment in North Dakota, highlighting its pro-agriculture and pro-energy stance, which aligns well with the company's operations [5] - The management team believes that the integration of ethanol production and carbon sequestration will lead to better economics and carbon scores for jet fuel production [29] - The company anticipates steady improvement in cash generation and financial flexibility, with a credible pathway to break-even operating cash flow [15] Other Important Information - The company has implemented Verity, a digital carbon tracking and verification platform, at its Gevo North Dakota facility, which is expected to enhance transparency and efficiency in carbon accounting [20][22] - A strategic partnership with Frontier Infrastructure Holdings aims to offer integrated carbon management solutions for ethanol producers [22] Q&A Session Summary Question: Can you elaborate on the incremental capital and steps required to optimize your operation and a reasonable timeline to achieve $110 million of EBITDA? - Management indicated that incremental capital is estimated at around $15 million, focusing on debottlenecking the ethanol plant and optimizing energy use [33][34] Question: Can you elaborate on the DOE loan extension and how it increases the likelihood of DOE financing? - Management noted that the shift of the loan guarantee to North Dakota reflects the project's attractiveness due to existing profitable operations and reduced financing needs [36][38] Question: What are the EBITDA drivers for next year? - Management highlighted that improvements in carbon intensity scores and operational efficiencies will be key drivers, with a focus on maximizing carbon value [40][43] Question: How should we project the incremental CI improvement over the next quarters? - Management explained that the CI score is expected to drop due to provisions in the One Big Beautiful Bill, which will enhance credit generation [71][74] Question: Can you update on conversations with potential customers for carbon sequestration services? - Management confirmed ongoing discussions with companies interested in co-locating to utilize the sequestration capacity, which could enhance profitability [65][66]

Financial Data and Key Metrics Changes - Assertio reported total product sales of $49.5 million for Q3 2025, up from $28.7 million in the prior year, primarily driven by the Rosedown two-quarter pull forward [13] - Adjusted EBITDA for Q3 2025 was $20.9 million, significantly up from $4.4 million in the prior year, largely due to higher Rosedown sales [16] - GAAP net income for Q3 2025 was $11.4 million, compared to a loss of $3 million in the prior year [16] Business Line Data and Key Metrics Changes - Rosedown net product sales reached $38.6 million in Q3 2025, a substantial increase from $15 million in the same quarter last year, attributed to the pull forward of sales [7] - Synthesan net product sales grew to $2.8 million in Q3 2025, up from $2.6 million in the prior year, driven by higher volume [8][13] - Indocin sales decreased to $4.8 million in Q3 2025 from $5.7 million in the prior year, reflecting impacts from generic competition [14] Market Data and Key Metrics Changes - Rosedown achieved a 43% market share in the clinic Medicare Part B segment in Q3 2025, reflecting strong demand and strategic distribution efforts [10] - The company experienced a 42% year-to-date demand growth for Rosedown compared to the same period in 2024 [10] Company Strategy and Development Direction - The company aims to maintain price stability and predictability for Rosedown while pursuing further demand and market share growth [12] - Assertio is currently reviewing and refining its strategies moving forward under new leadership, focusing on growth assets [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's potential to generate significant value for patients and shareholders, highlighting a solid balance sheet and core growth assets [6] - The company anticipates a temporary decline in cash flow due to the Rosedown sales transition but expects improvement in Q2 2026 [16] Other Important Information - Assertio has executed a long-term supply agreement with its API manufacturer, ensuring stable supply and pricing for Rosedown [11] - The company is tightening its 2025 guidance, expecting full-year product sales between $110 million and $112 million and adjusted EBITDA between $14 million and $16 million [17] Q&A Session Summary Question: Linkage between labeler code and ASP for Rosedown - Management clarified that the labeler code change is not tied to ASP and emphasized a strategy of price stability and predictability [20] Question: Comments on Indocin market performance - Management noted good market share and volume for Indocin despite competition, with some price favorability observed [21] Question: Optimizing Rosedown's promotional and reimbursement strategy - Management is currently reviewing all strategies and will provide updates as refinements are made [24] Question: Expectations for Synthesan sales acceleration - Management indicated that Synthesan is competing in a generic market with a focus on raising awareness and promoting its unique delivery mechanism [30]

Financial Data and Key Metrics Changes - Total cash and investments at the end of Q3 2025 amounted to $715 million, including $457 million in cash and $258 million in held maturity securities [25] - Q3 2025 revenue was $33.1 million, a decrease of $8.4 million year-over-year, primarily due to lower volume on army programs [26] - Gross margin for Q3 2025 was 22.4%, down from 25.9% in the same period last year, attributed to the absence of certain higher-margin programs [26] - SG&A expenses increased from $17.5 million in Q3 2024 to $25.3 million in Q3 2025, driven by higher labor costs and strategic initiatives [26][27] - Net income for Q3 was $2.5 million, impacted by a decrease in the fair value of derivatives [27] - Adjusted EBITDA for Q3 was negative $9.4 million, compared to positive $900,000 in the prior year, due to increased SG&A and lower gross profit [27] Business Line Data and Key Metrics Changes - The acquisition of AskSage is expected to significantly enhance BigBear.ai's capabilities in delivering secure AI solutions for defense and national security agencies [5][12] - AskSage's annual recurring revenue (ARR) is projected to grow over six times from 2024 to 2025, reaching $25 million in ARR [5][16] Market Data and Key Metrics Changes - The number of federal GenAI use cases has increased over eight times since 2023, indicating a growing market for generative AI solutions [16] - BigBear.ai's Veriscan biometric platform has expanded to additional airports, enhancing security and processing times [21] Company Strategy and Development Direction - The company is focused on organic growth and disciplined M&A to strengthen its position in the national security market, particularly through the acquisition of AskSage [4][20] - The M&A strategy targets disruptive AI mission solutions, smart travel and trade technologies, and platform-level AI technologies [9][10][11] - The integration of AskSage is expected to create synergies by cross-selling products and enhancing the existing customer base [19] Management's Comments on Operating Environment and Future Outlook - Management acknowledges risks related to the ongoing government shutdown but maintains a revenue projection of $125 million to $140 million for the full year 2025 [28] - The company is positioned to capitalize on unprecedented government AI investments expected in 2026 and 2027 [20] - Management emphasizes the importance of talent acquisition and development to support growth initiatives [30] Other Important Information - The company raised approximately $337 million through the sale of 65 million shares, allowing for continued execution of its M&A strategy [25][26] - The acquisition of AskSage is anticipated to close late in Q4 2025 or early Q1 2026, with no material impact on 2025 financial results expected [28] Q&A Session Summary - No specific questions and answers were provided in the content, thus this section is not applicable.

Financial Data and Key Metrics Changes - The company reported $177 million in revenue for Q3 2025, with a 46% sequential increase and a 13% year-over-year increase in the GenEco electrolyzer business, which generated approximately $65 million [5][12] - Operating cash burn improved by over 50% from the prior quarter, indicating better pricing discipline and tighter working capital management [5][6] - The company is targeting $700 million in revenue for the full year 2025 [90] Business Line Data and Key Metrics Changes - The GenEco electrolyzer business is on track for a record year with expected sales of around $200 million, reflecting a 33% year-over-year increase [12][13] - The material handling business continues to perform well, with major customers like Amazon and Walmart planning to expand their fleets [11][50] - The company has delivered its first 10-megawatt electrolyzer to the GALP project in Portugal, part of a larger 100-megawatt installation [14][52] Market Data and Key Metrics Changes - The hydrogen production network has shown improvements, with the Georgia Green Hydrogen Plant achieving 324 tons of production with 97% uptime and 92.8% efficiency [7] - The company is seeing strong government support for green hydrogen projects in Australia and Europe, with many projects expected to reach final investment decision (FID) in the next 12-18 months [13][14] Company Strategy and Development Direction - The company is focused on Project Quantum Leap, which aims to simplify the business, align investments for near-term profitability, and resolve legacy issues [6][9] - A strategic initiative to monetize electricity rights is expected to generate over $275 million in liquidity, positioning the company in the growing data center market [7][30] - The company has suspended activities under the DOE loan program to redeploy capital towards higher return opportunities [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver continual margin improvement and cash flow gains, emphasizing a strong balance sheet and disciplined capital allocation [9][10] - The transition of leadership to Jose Luis Crespo is seen as a continuity in strategy, with a focus on growth, profitability, and disciplined execution [10][50] - Management highlighted the importance of the investment tax credit for fuel cells, which strengthens the financial case for customers [12][50] Other Important Information - The company has over 230 megawatts of GenEco electrolyzer programs underway across various regions, showcasing its operational scale [6] - The company is actively pursuing opportunities in the data center market, leveraging its hydrogen solutions for backup power [30][39] Q&A Session Summary Question: What is the expected cadence of fuel margin improvements? - Management indicated a progression in margins, with expectations for a significant improvement in Q4 and a target for break-even by mid-2026 [19][21] Question: Can you provide expectations on the growth cadence for the electrolyzer business? - Management refrained from providing specific guidance for 2026 but indicated strong growth momentum and a robust project pipeline [22][24] Question: How does the company plan to leverage the data center and AI revolution? - The company is exploring opportunities to provide backup power using hydrogen for data centers, with a focus on liquidity and strategic partnerships [29][30] Question: What are the growth drivers expected over the next couple of years? - Management highlighted the potential for growth in the electrolyzer market, material handling, and the data center market as key areas of focus [78][80] Question: Will the company consider divesting or monetizing its liquefaction sites? - Management expressed no intention to divest these assets, as they provide cost-competitive hydrogen and a strong negotiating position [87] Question: What is the outlook for cash burn and runway? - Management expects continued reduction in cash burn and a strong balance sheet to support operations through to positive cash flows [68][70]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $5.3 million, down from $7.5 million in the prior year period, primarily due to lower government sector revenues caused by funding delays [10] - Government revenue for Q3 was $4.1 million compared to $6.9 million in the prior year, while international revenue increased to $1.2 million from $0.4 million [10] - Gross profit for Q3 was $3.5 million, or 66% of total revenue, down from $5.5 million, or 73% in the prior year [10] - Net loss for Q3 was $0.4 million, or $0.03 per diluted share, compared to net income of $0.6 million, or $0.05 per diluted share in the prior year [12] Business Line Data and Key Metrics Changes - The STEP program remains a strong selling point, particularly for smaller agencies, driving consistent adoption and high renewal rates, contributing to recurring revenue [6] - The introduction of the V1 portable simulator is aimed at expanding the addressable market for smaller departments [7] - International revenue more than doubled compared to the same period last year, indicating growing global recognition of VirTra's training solutions [8] Market Data and Key Metrics Changes - The operating environment is affected by federal funding delays, with agency procurement cycles moving slower than normal due to budget clarity and grant awards [4] - The Department of Justice COPS Grants Program has identified agencies for funding, but announcements were delayed due to federal shutdowns [4] - Military work is progressing, with a successful demonstration of the Soldier Virtual Trainer system for the U.S. Army [8] Company Strategy and Development Direction - The company is focused on improving sales processes, products, and operations to strengthen its foundation and prepare for growth as funding resumes [15] - The recent entry into the GSA procurement cycle channel is expected to streamline sales processes and shorten delivery timelines [5] - The updated STEP program with three-year commitments enhances recurring revenue visibility and reinforces long-term customer relationships [14] Management's Comments on Operating Environment and Future Outlook - Management noted that while the operating environment is challenging due to funding delays, there is strong engagement with customers and a growing backlog of opportunities [3] - The company anticipates improved revenue conversions once grant awards and customer acceptance pick up [4] - Management expressed optimism about future growth as funding resumes and highlighted the importance of building relationships with military partners [9] Other Important Information - Cash and cash equivalents as of September 30, 2025, totaled $20.8 million, up from $18 million at the end of 2024 [13] - Backlog as of September 30, 2025, stood at $21.9 million, with $10.2 million in capital, $5.3 million in service, and $6.4 million in STEP contracts [14] Q&A Session Summary Question: Were there any multi-year deals that skewed booking results? - A booking of about $4.8 million was received at the end of the quarter, primarily from an international customer, which is expected to convert to revenue in 2026 [17] Question: How does the funding backdrop impact military prospects? - The funding shutdown affects both military and police agency businesses, with significant reliance on government funding [19] Question: Can you break down the backlog in terms of funded versus unfunded? - The backlog includes $10.2 million in capital, with conversion dependent on customer purchasing and readiness [22][24] Question: Is the company considering acquisitions or buybacks? - The company is strategically waiting for funding clarity before considering acquisitions, focusing on technologies that align with its core offerings [26] Question: What is the outlook for gross margins going forward? - Gross margins are expected to remain similar to current levels, with a potential slight decrease, aiming for a range between 60% and 65% [30]

Financial Data and Key Metrics Changes - For Q1 2026, the company reported net income of $1.293 million on revenues of $226.7 million, translating to $0.03 per share, a decrease of approximately 61.7% from $3.376 million on $203.6 million of revenues in Q1 2025 [8][9] - Adjusted EBITDA for Q1 2026 was $6.8 million, down 28.1% from $9.452 million in Q1 2025. Excluding a one-time bad debt expense of $1.3 million, adjusted EBITDA would have been $8.1 million, slightly above the previous quarter [3][9] Business Line Data and Key Metrics Changes - The growth in transportation revenues was primarily driven by acquisition efforts, with organic growth opportunities emerging in contract logistics, customs services, and technology services [3][4] - The Navigate platform is expected to be a significant driver of organic growth, enhancing visibility and decision-making for customers [4][6] Market Data and Key Metrics Changes - The company remains virtually debt-free, with net debt of approximately $2 million against a $200 million credit facility, indicating a strong financial position [5] - The acquisition of WePort in Mexico is seen as a strategic move to enhance capabilities in a key market, supporting existing and new customers [5][33] Company Strategy and Development Direction - The company aims to balance capital allocation through strategic acquisitions, stock buybacks, and investments in sales resources, particularly focusing on the deployment of Navigate technology [6][47] - The management emphasizes a disciplined approach to capital allocation and a durable business model to navigate the challenging freight environment [4][5] Management's Comments on Operating Environment and Future Outlook - The management acknowledges a difficult freight market, particularly for international business, but notes early signs of improvement in over-the-road brokerage pricing [20][21] - The company is optimistic about the potential of Navigate to drive organic growth and enhance customer engagement over the coming quarters [18][19] Other Important Information - The company executed a stock buyback program, acquiring $0.8 million of its stock in Q1 2026 and an additional $2.8 million post-quarter [5] - The management is exploring opportunities to recover some of the $1.3 million bad debt related to the First Brands bankruptcy, although clarity on this remains uncertain [33][35] Q&A Session Summary Question: How should we think about Navigate's deployment and customer adoption? - The management indicated that they are in the early stages of deploying Navigate, which has been integrated with their core technology stack, and they expect to see incremental organic growth from this offering in the coming quarters [12][14] Question: What are the expectations for the current quarter in the freight market? - The management noted that the freight market remains challenging, but they anticipate some improvements in brokerage operations and value-added services [20][21] Question: Can you provide updates on the WePort acquisition and the impact of First Brands bankruptcy? - The management expressed excitement about the WePort acquisition, highlighting its strategic importance in Mexico, and acknowledged the unexpected nature of the First Brands bankruptcy, while exploring potential recovery options [33][35]

Financial Data and Key Metrics Changes - For Q3 2025, the company reported R&D expenses of $10.3 million, an increase from $6.8 million in the same period last year, primarily due to expenses related to the DRAGON and Phoenix trials [5] - G&A expenses rose to $12.7 million from $2.9 million year-over-year, driven by increased share-based compensation expenses [5] - The net loss for Q3 2025 was $21.7 million, compared to a net loss of $8.7 million for the same period last year [5] - Total operating cash outflow for Q3 was approximately $9.3 million, similar to $8.6 million in Q2 [6] - At the end of Q3, the company had $275.6 million in cash and liquidity from time deposits and US Treasury bills [6] Business Line Data and Key Metrics Changes - The company completed enrollment for the phase 3 Phoenix trial with 530 subjects and the phase 3 DRAGON trial, with approximately 35 subjects enrolled out of a targeted 60 [3][4] - Positive feedback was received from regulatory authorities, including China's NMPA and the U.K.'s MHRA, regarding the DRAGON trial [4] Market Data and Key Metrics Changes - The company is preparing for submissions in multiple regions, including the U.S., Japan, and the U.K., with a focus on maintaining a consistent data package across regulatory agencies [8][14] - The company plans to submit applications in the first half of 2026 for regulatory approval in China and the U.K. [8] Company Strategy and Development Direction - The company is focused on advancing clinical trials and preparing for commercialization, with a strong balance sheet to support these efforts [6] - The U.S. market is prioritized for commercialization, with plans to apply for NDA in all regions, while seeking partnerships for other markets [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong foundation provided by the DRAGON trial for global submissions and potential approvals [4] - The company estimates that approximately $200 million will be needed for the commercialization of Saga in the U.S. [25] Other Important Information - The company completed a $50 million registered direct offering and a $125 million private placement, with potential for an additional $165 million upon full bond exercise [4] - The increase in share-based compensation expenses was a significant factor in the overall expense increase [6] Q&A Session Summary Question: Has the application been submitted to regulatory agencies in China and the U.K.? - The company plans to submit applications in the first half of 2026 [8] Question: What is the current amount of shares outstanding? - The total outstanding shares are approximately 35 million [10] Question: When will the application be submitted in Japan? - The expected timeline for submission in Japan is also the first half of 2026 [14] Question: Will there be an interim analysis for the Phoenix trial similar to the DRAGON trial? - Yes, an interim analysis is planned for the second half of next year [16] Question: What should be assumed as the baseline level for SG&A expenses going forward? - It is difficult to estimate a clear baseline due to the variability related to share price and ESOP [18] Question: What steps are being taken to prepare for potential approval and launch? - The focus is on the U.S. market, with plans to start with a sales force of 20 to 40 people [23] Question: Is the current cash sufficient for commercial preparation and launch? - The company estimates that $200 million will be needed for commercialization, and believes current cash should be sufficient [25] Question: Did the U.K. request the same interim information as the U.S. FDA? - Yes, the same dataset was presented to both the U.K. and China [30]

Financial Data and Key Metrics Changes - Total net revenue for Q3 2025 was $3.2 million, up from $2.2 million in the prior quarter and down from $3.8 million in Q3 2024 [19] - GAAP gross margin increased to 56.2% in Q3 2025 from 48.3% in the prior quarter and 47% in the same quarter a year ago [21] - Non-GAAP gross margin for Q3 2025 was also 56.2%, compared to 48.3% in the prior quarter and 61.7% in Q3 2024 [22] - GAAP operating expenses for Q3 2025 were $3 million, down from $4.5 million in Q3 2024 [22] - Non-GAAP net loss for Q3 2025 was $1.7 million or a loss of $0.28 per share, compared to a loss of $2.7 million or $0.98 per share in the prior quarter [23] Business Line Data and Key Metrics Changes - Revenue from millimeter wave products was $3 million in Q3 2025, compared to $2.2 million in the prior quarter and $0.1 million in Q3 2024 [20] - The increase in revenue was primarily driven by a favorable revenue mix of millimeter wave products and solutions [21] Market Data and Key Metrics Changes - The company noted a steady recovery in market demand and customer orders for its 60 GHz wireless solutions, particularly in the fixed wireless access market [6][7] - The company highlighted significant wins in fixed wireless access, including partnerships with Tachyon Networks and WeLink Communications [9][10] Company Strategy and Development Direction - The company is focusing on expanding its millimeter wave solutions into new markets, including tactical communications for military applications [11][12] - The management emphasized the versatility of its technology, which can support high-bandwidth video for edge AI applications [14][15] - The company is committed to disciplined expense management while driving growth in its millimeter wave product lines [19] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of the renewed momentum in the fixed wireless access market [7] - The company expects total net revenue for Q4 2025 to be in the range of $2.8 million to $3.1 million based on current backlog [25] Other Important Information - The company had approximately $1.9 million in cash as of September 30, 2025, compared to $1.8 million as of June 30, 2025 [24] - The strategic review process is ongoing, with no new updates provided during the call [24] Q&A Session Summary Question: Can you provide more details on the new OEM announced? - The new OEM is a significant player in the space, and the company is optimistic about the opportunity, although specifics cannot be disclosed due to confidentiality [26][27] Question: What is the expected timeline for customer production schedules? - The typical engagement to mass production timeline is 9-12 months for fixed wireless, while new markets like military may take 12-15 months [29] Question: How should the market view the increase in inventory and accounts receivable? - The increase in accounts receivable was due to timing of sales, and inventory was built to meet anticipated demand for Q1 and Q2 [30][31] Question: What is the outlook for gross margin going forward? - The company aims to maintain gross margins around 50%, with some fluctuations based on product mix and inventory sales [32][33] Question: How long does it typically take for pre-production customers to contribute to revenue? - Once a customer reaches pre-production, it typically takes about three months before they start contributing meaningfully to revenue [34]

Financial Data and Key Metrics Changes - The company ended Q3 2025 with cash, cash equivalents, and investments of $593.6 million, a significant increase from $198.2 million as of December 31, 2024, indicating strong liquidity to support operations into 2028 [16] - R&D expenses for Q3 2025 were $31.5 million, down from $54 million in Q3 2024, primarily due to the conclusion of the lorandirostat pivotal program [16][17] - Net loss for Q3 2025 was $36.9 million, a decrease from $56.3 million in Q3 2024, reflecting improved expense management [18] Business Line Data and Key Metrics Changes - The company is advancing its clinical programs, particularly lorandirostat, which has shown clinically meaningful reductions in systolic blood pressure across diverse patient populations [6][10] - The EXPLORE-CKD trial demonstrated a significant reduction in systolic blood pressure and a clinically meaningful reduction in urinary albumin-creatinine ratio, indicating potential renal protection [10] Market Data and Key Metrics Changes - The company is focusing on market access planning and payer engagement to ensure the value of lorandirostat is well understood, which is crucial for its commercial readiness [13] - The ongoing phase II EXPLORE-OSA trial aims to evaluate lorandirostat's efficacy in patients with obstructive sleep apnea and hypertension, with results expected in Q1 2026 [11] Company Strategy and Development Direction - The company is preparing for an NDA submission for lorandirostat, expected by the end of 2025 or early 2026, following positive pre-NDA feedback from the FDA [5][36] - The strategy includes expanding lorandirostat's profile to address comorbid conditions associated with hypertension, such as chronic kidney disease and obstructive sleep apnea [12][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the clinical data supporting lorandirostat as a best-in-class therapy for uncontrolled and resistant hypertension [14][64] - The company is optimistic about upcoming milestones, including the NDA submission and results from the EXPLORE-OSA trial, which could enhance the drug's profile [64] Other Important Information - The company has emphasized the importance of diverse patient representation in clinical trials, particularly for Black or African American populations, which are often underrepresented in hypertension studies [54] - The management highlighted the need for partnerships to maximize the value of lorandirostat, both in the U.S. and internationally [38][49] Q&A Session Summary Question: What would the systolic blood pressure reduction be without adjusting for discontinuations? - Management indicated that they have not performed that specific analysis, as it was not part of the study plan [20][21] Question: Have you looked at the day and night blood pressure differences in the Advanced HTN trial? - Management confirmed that they are comfortable with the 24-hour control and have measured blood pressure at trough, but have yet to publish nighttime data [26][28] Question: Can you provide more details on the pre-NDA feedback? - Management stated that there were no surprises in the feedback and expressed confidence in the data set prepared for submission [35][36] Question: What are your expectations for the open label extension trial? - Management noted that the trial is progressing well, with no surprises, and results will be published once the last subject completes the study [40] Question: How do you expect to leverage data from the EXPLORE-OSA trial? - Management aims to enhance lorandirostat's profile by demonstrating its benefits beyond blood pressure reduction, addressing related comorbidities [41] Question: What differences in efficacy do you see with lorandirostat in the African American population? - Management highlighted that over 50% of participants in the Advance HTN trial were Black or African American, showing that race does not determine response to lorandirostat [54][56]

Financial Data and Key Metrics Changes - Q3 2025 revenue was $240 million, a slight year-over-year decrease of 0.2% and 2% on a currency-neutral basis [4][9] - Adjusted EBITDA for the quarter was $78.7 million, down 2.4% reported and 4.4% on a currency-neutral basis, with a margin of 32.8% [4][16] - Free cash flow improved to $7.9 million compared to negative $1.8 million in Q3 2024 [17] - Total debt outstanding was $1.38 billion, with net leverage at 4.3 times, slightly up from 4.2 times in Q3 2024 [18] Business Line Data and Key Metrics Changes - Creative revenue was $144.9 million, up 8.4% year-on-year, driven by Premium Access revenue [11][12] - Editorial revenue was $89.3 million, down 3.7% year-on-year, primarily due to declines in news and sports [13] - Agency revenue declined 22% year-on-year, reflecting ongoing macro uncertainty [12][13] Market Data and Key Metrics Changes - Revenue growth in the Americas was 0.8% on a currency-neutral basis, while EMEA was down 4% and APAC down 10.8% [15] - Annual subscription revenue increased to 58.4% of total revenue, up from 52.4% in Q3 2024, with growth driven by Premium Access [10] Company Strategy and Development Direction - The company is focusing on AI initiatives, including partnerships for content licensing with technology platforms [5][25] - The merger with Shutterstock is a key strategic focus, with ongoing regulatory reviews impacting the timeline [6][19] - The company aims to enhance operational efficiency through AI deployment within its business functions [26] Management's Comments on Operating Environment and Future Outlook - Management noted headwinds from tough year-on-year comparisons due to a strong editorial calendar in Q3 2024 [9][21] - The company updated its full-year revenue guidance to $942 million-$951 million, reflecting a year-on-year growth of 0.3%-1.2% [21][22] - Management expressed optimism about the potential for AI-related revenue streams in the future [25] Other Important Information - The company is facing legal challenges, including a favorable ruling in a trademark infringement case against Stability AI [7][8] - SG&A expenses increased to $101 million, primarily due to SOX compliance efforts and ongoing litigation costs [15][16] Q&A Session Summary Question: Can you elaborate on Getty's key AI initiatives and their potential revenue impacts for 2026? - Management highlighted multiple licensing deals, including a confidential agreement with Perplexity, which could develop into a material revenue stream [24][25] Question: How are the corporate and media customer segments performing? - Media segment saw a 3% decline, particularly in broadcast and production, while corporate segment remains healthy with close to 100% retention [27][28] Question: What is the retention rate for Premium Access subscriptions? - Premium Access has the highest retention rates among subscriptions, remaining consistent over time [29][30] Question: What drove the sequential recovery in creative revenue? - The recovery was attributed to a normalization of revenue allocation between creative and editorial, along with a significant deal that provided upfront revenue recognition [32][34]